MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MDxHealth S.A.NASDAQ: MDXH
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns negative
Q2 FY2026 EBITDA was -$1.01M, compared with $770K a year earlier.
Context
- EBITDA amounted to 13.0% of revenue in FY2025, down 11.5 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$8.29M (+40.8%) for the fiscal year ending Dec 2026, a step up from the +36.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$1.01M— QoQ
- Last fiscal yearDec 2025
- -$14.01M+36.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -230.6% | — | — |
| 1 year | +36.4% | +40.8% | +4.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (14.01M) USD
- Year-over-year change
- +36.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.01M) | +36.4% |
| FY2024 | 2024-12-31 | (22.02M) | +27.7% |
| FY2023 | 2023-12-31 | (30.47M) | +16.3% |
| FY2022 | 2022-12-31 | (36.39M) | -51.1% |
| FY2021 | 2021-12-31 | (24.09M) | — |
EBITDA vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's FY2025 EBITDA of -$14.01M is the 5th highest of the 11 companies compared; the peer median is -$30.61M.
- Its year-over-year change of +36.4% is the 4th highest of 11, against a peer median of -2.4%.
- EBITDA amounts to 13.0% of revenue for MDXH, versus a peer median of 54.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.67M | +217.1% | +59.4% | 51.1% | |
| LTM Jun 2026 | $12.89M | +145.3% | — | 1.7% | |
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
| LTM Mar 2026 | -$12.91M | -11.7% | — | 18.9% | |
| FY2025 | -$14.01M | +36.4% | — | 13.0% | |
| LTM Mar 2026 | -$20.09M | +16.9% | — | 64.4% | |
| LTM Mar 2026 | -$41.14M | -191.1% | — | 76.3% | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Mar 2026 | -$70.61M | -31.5% | — | 843.9% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
| LTM Mar 2026 | -$84.67M | -104.0% | — | 58.4% | |
| Peer median (excluding MDXH) | -$30.61M | -2.4% | +59.4% | 54.8% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 22.24M | 37.05M | 70.19M | 90.05M | 107.88M |
| Cost of Revenue | 11.68M | 17.84M | 26.26M | 34.91M | 43.43M |
| Gross Profit | 10.56M | 19.22M | 43.93M | 55.14M | 64.44M |
| Gross Margin | 47.5% | 51.9% | 62.6% | 61.2% | 59.7% |
| Research & Development | 5.59M | 7.56M | 6.38M | 10.55M | 10.35M |
| Selling, General & Admin | 30.22M | 50.12M | 59.93M | 61.4M | 66.75M |
| Operating Expenses | 37.41M | 57.12M | 71.26M | 79.86M | 79.84M |
| Depreciation & Amortization | 3.04M | 4.91M | 6.86M | 8.04M | 9.21M |
| EBITDA | (24.09M) | (36.39M) | (30.47M) | (22.02M) | (14.01M) |
| EBITDA Margin | -108.3% | -98.2% | -43.4% | -24.5% | -13.0% |
| Operating Income | (26.84M) | (37.9M) | (27.33M) | (24.72M) | (15.4M) |
| Operating Margin | -120.7% | -102.3% | -38.9% | -27.5% | -14.3% |
| Interest Income | 11K | 125K | 1.09M | 1.08M | 1.5M |
| Interest Expense | 1.88M | 2.74M | 5.77M | 7.63M | 12.16M |
| Other Income / Expenses | (2.16M) | (6.14M) | (15.77M) | (12.97M) | (19.98M) |
| Income Before Tax | (29M) | (44.04M) | (43.1M) | (37.69M) | (35.38M) |
| Pre-Tax Margin | -130.4% | -118.9% | -61.4% | -41.9% | -32.8% |
| Income Tax Expense | 0 | 0 | 1K | 382K | (1.86M) |
| Net Income | (29M) | (44.04M) | (43.1M) | (38.07M) | (33.52M) |
| Net Margin | -130.4% | -118.9% | -61.4% | -42.3% | -31.1% |
| EPS (Basic) | (2.38) | (2.78) | (1.66) | (0.78) | (0.67) |
| EPS (Diluted) | (2.38) | (2.78) | (1.66) | (1.16) | (0.67) |
| Weighted Avg Shares | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
| Weighted Avg Shares (Diluted) | 12.19M | 15.87M | 25.91M | 48.67M | 50.03M |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.